Novavax reported 271.08M in Cost of Sales for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Cost Of Sales Change
TG Therapeutics TGTX:US 23K 214K
Adma Biologics ADMA:US $ 26.14M 0.7M
Agenus AGEN:US $ 2.02M 1.48M
Astrazeneca AZN:US 1.9B 375M
AstraZeneca AZN:LN 156386.94M 17145.23M
Biocryst Pharmaceuticals BCRX:US $ 0.25M 0.01M
Dynavax Technologies DVAX:US $ 83.37M 43.41M
GlaxoSmithKline GSK:LN 213600M 55400M
Mannkind MNKD:US $ 12.92M 1.92M
Merk MRK:US $ 3698M 1636M
Moderna Inc MRNA:US 1.38B 364M
Novartis NVS:US $ 3749M 6M
Novavax NVAX:US 271.08M 255.87M
Peregrine Pharmaceuticals PPHM:US $ 27.58M 3.33M
Pfizer PFE:US $ 8671M 1339M
Sarepta Therapeutics SRPT:US $ 37.8M 6.35M